贝伐珠单抗是一种抗血管内皮生长因子 (VEGF) 单克隆抗体，可抑制血管生成并减少肿瘤生长。据报道，血清 VEGF-C、乳酸脱氢酶和炎症标志物是与贝伐珠单抗治疗相关的预测标志物。程序性细胞死亡配体1（PD-L1）可作用于VEGF受体2，诱导癌细胞血管生成和转移。根据PD-L1的表达情况探讨含贝伐单抗化疗对转移性结直肠癌（CRC）患者的疗效该分析包括 2014 年 6 月 24 日至 2022 年 2 月 28 日期间在三星医疗中心（韩国首尔）接受贝伐珠单抗加 FOLFOX 或 FOLFIRI 作为一线治疗的 CRC 患者。患者数据分析包括通过综合阳性评分 (CPS) 评估 PD-L1 表达。我们根据 CRC 患者的 PD-L1 表达状态分析了贝伐珠单抗的疗效。本次分析总共纳入了 124 名患者。几乎所有患者均接受贝伐单抗联合 FOLFIRI 或 FOLFOX 作为一线化疗。 77% 的患者接受 FOLFOX，23% 的患者接受 FOLFIRI 作为主要一线化疗。 PD-L1 CPS 为 1 或以上、5 或以上、10 或以上的患者人数分别为 105 名（85%）、64 名（52%）和 32 名（26%）。结果显示，贝伐珠单抗治疗的 PD-L1 CPS 小于 1 的患者与 PD-L1 CPS 等于 1 或以上的患者（PD-L1 < 1）的无进展生存期 (PFS) 和总生存期 (OS) 无显着差异。 % vs PD-L1 ≥ 1%；PFS：P = 0.93，OS：P = 0.33），PD-L1 CPS 小于 5 和 5 或以上的患者之间（PD-L1 < 5% vs PD-L1 ≥ 5） PFS：P = 0.409，OS：P = 0.746），以及 PD-L1 CPS 小于 10 和 10 或以上的患者之间（PD-L1 < 10% vs PD-L1 ≥ 10%；PFS：P = 0.529，OS：P = 0.568）。无论 PD-L1 表达如何，含贝伐珠单抗的化疗均可被视为转移性 CRC 的一线治疗。©作者 2024。百事登出版集团有限公司出版。保留所有权利。

Bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, inhibits angiogenesis and reduces tumor growth. Serum VEGF-C, lactate dehydrogenase, and inflammatory markers have been reported as predictive markers related to bevacizumab treatment. Programmed cell death ligand 1 (PD-L1) could act upon VEGF receptor 2 to induce cancer cell angiogenesis and metastasis.To investigate the efficacy of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer (CRC) according to the expression of PD-L1.This analysis included CRC patients who received bevacizumab plus FOLFOX or FOLFIRI as first-line therapy between June 24, 2014 and February 28, 2022, at Samsung Medical Center (Seoul, South Korea). Analysis of patient data included evaluation of PD-L1 expression by the combined positive score (CPS). We analyzed the efficacy of bevacizumab according to PD-L1 expression status in patients with CRC.A total of 124 patients was included in this analysis. Almost all patients were treated with bevacizumab plus FOLFIRI or FOLFOX as the first-line chemotherapy. While 77% of patients received FOLFOX, 23% received FOLFIRI as backbone first-line chemotherapy. The numbers of patients with a PD-L1 CPS of 1 or more, 5 or more, or 10 or more were 105 (85%), 64 (52%), and 32 (26%), respectively. The results showed no significant difference in progression-free survival (PFS) and overall survival (OS) with bevacizumab treatment between patients with PD-L1 CPS less than 1 and those with PD-L1 CPS of 1 or more (PD-L1 < 1% vs PD-L1 ≥ 1%; PFS: P = 0.93, OS: P = 0.33), between patients with PD-L1 CPS less than 5 and of 5 or more (PD-L1 < 5% vs PD-L1 ≥ 5%; PFS: P = 0.409, OS: P = 0.746), and between patients with PD-L1 CPS less than 10 and of 10 or more (PD-L1 < 10% vs PD-L1 ≥ 10%; PFS: P = 0.529, OS: P = 0.568).Chemotherapy containing bevacizumab can be considered as first-line therapy in metastatic CRC irrespective of PD-L1 expression.©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.